KR20210049778A - 질병 상태 및 병태를 치료하는데 사용하기 위한 거울상 이성질체적으로 정제된 gper 작용제 - Google Patents

질병 상태 및 병태를 치료하는데 사용하기 위한 거울상 이성질체적으로 정제된 gper 작용제 Download PDF

Info

Publication number
KR20210049778A
KR20210049778A KR1020217002117A KR20217002117A KR20210049778A KR 20210049778 A KR20210049778 A KR 20210049778A KR 1020217002117 A KR1020217002117 A KR 1020217002117A KR 20217002117 A KR20217002117 A KR 20217002117A KR 20210049778 A KR20210049778 A KR 20210049778A
Authority
KR
South Korea
Prior art keywords
degrees
cancer
disease
derivative
srr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217002117A
Other languages
English (en)
Korean (ko)
Inventor
크리스토퍼 나탈레
패트릭 무니
티나 개리앤테스
웨인 루크
Original Assignee
리니어스 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리니어스 테라퓨틱스, 인코포레이티드 filed Critical 리니어스 테라퓨틱스, 인코포레이티드
Publication of KR20210049778A publication Critical patent/KR20210049778A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020217002117A 2018-07-21 2019-07-22 질병 상태 및 병태를 치료하는데 사용하기 위한 거울상 이성질체적으로 정제된 gper 작용제 Ceased KR20210049778A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701726P 2018-07-21 2018-07-21
US62/701,726 2018-07-21
PCT/US2019/042827 WO2020023391A1 (en) 2018-07-21 2019-07-22 Enantiomerically purified gper agonist for use in treating disease states and conditions

Publications (1)

Publication Number Publication Date
KR20210049778A true KR20210049778A (ko) 2021-05-06

Family

ID=69160978

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217002117A Ceased KR20210049778A (ko) 2018-07-21 2019-07-22 질병 상태 및 병태를 치료하는데 사용하기 위한 거울상 이성질체적으로 정제된 gper 작용제

Country Status (23)

Country Link
US (6) US20200024262A1 (https=)
EP (2) EP3823617B1 (https=)
JP (2) JP2021532148A (https=)
KR (1) KR20210049778A (https=)
CN (1) CN112469409B (https=)
AU (1) AU2019310029B2 (https=)
BR (1) BR112021001031A2 (https=)
CA (1) CA3107109A1 (https=)
DK (1) DK3823617T3 (https=)
ES (1) ES2980434T3 (https=)
FI (1) FI3823617T3 (https=)
HR (1) HRP20240661T1 (https=)
HU (1) HUE067185T2 (https=)
IL (2) IL312938A (https=)
LT (1) LT3823617T (https=)
MX (2) MX2021000809A (https=)
NZ (1) NZ771952A (https=)
PL (1) PL3823617T3 (https=)
PT (1) PT3823617T (https=)
RS (1) RS65599B1 (https=)
SI (1) SI3823617T1 (https=)
SM (1) SMT202400205T1 (https=)
WO (1) WO2020023391A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022091029A1 (en) * 2020-10-30 2022-05-05 Resverlogix Corp. Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
US20240376547A1 (en) * 2021-04-08 2024-11-14 Linnaeus Therapeutics, Inc. Oncologic variations associated with cancer and methods of treatment
WO2022245899A2 (en) * 2021-05-19 2022-11-24 Linaeus Therapeutics, Inc. Diagnostic methods and compositions for treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US251870A (en) * 1882-01-03 Automatic gate
US6809104B2 (en) * 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US7875721B2 (en) * 2005-08-04 2011-01-25 Stc.Unm Compounds for binding to ERα/β and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof
WO2008153945A2 (en) * 2007-06-06 2008-12-18 University Of South Florida Nutraceutical co-crystal compositions
MX382354B (es) * 2010-11-01 2025-03-13 Celgene Car Llc Compuestos heterocíclicos y usos de los mismos.
US10251870B2 (en) * 2015-03-06 2019-04-09 Stc.Unm Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity
AU2016246688B2 (en) * 2015-04-06 2020-11-12 The Trustees Of The University Of Pennsylvania Compositions and methods for decreasing, or preventing or reversing gain of, skin pigmentation in a mammalian subject
US11369618B2 (en) 2016-06-17 2022-06-28 The Trustees Of The University Of Pennsylvania Compounds, compositions and methods for prevention and/or treatment of cancer

Also Published As

Publication number Publication date
CN112469409B (zh) 2026-03-13
EP4356913A2 (en) 2024-04-24
US20230382896A1 (en) 2023-11-30
HUE067185T2 (hu) 2024-10-28
SI3823617T1 (sl) 2024-09-30
HRP20240661T1 (hr) 2024-08-16
US20220089576A1 (en) 2022-03-24
JP2021532148A (ja) 2021-11-25
MX2024008188A (es) 2024-07-19
NZ771952A (en) 2026-01-30
AU2019310029B2 (en) 2025-05-29
PL3823617T3 (pl) 2024-08-12
US20250171421A1 (en) 2025-05-29
RS65599B1 (sr) 2024-06-28
CN112469409A (zh) 2021-03-09
IL280283A (en) 2021-03-01
IL312938A (en) 2024-07-01
US11760749B2 (en) 2023-09-19
PT3823617T (pt) 2024-06-03
JP2024119868A (ja) 2024-09-03
US20200024262A1 (en) 2020-01-23
WO2020023391A1 (en) 2020-01-30
US20200140417A1 (en) 2020-05-07
EP3823617B1 (en) 2024-03-06
US20220033385A1 (en) 2022-02-03
DK3823617T3 (da) 2024-06-03
US10934277B2 (en) 2021-03-02
SMT202400205T1 (it) 2024-07-09
FI3823617T3 (fi) 2024-05-29
ES2980434T3 (es) 2024-10-01
AU2019310029A1 (en) 2021-02-04
LT3823617T (lt) 2024-07-10
MX2021000809A (es) 2021-06-15
BR112021001031A2 (pt) 2021-04-13
EP4356913A3 (en) 2024-06-26
CA3107109A1 (en) 2020-01-30
IL280283B1 (en) 2024-06-01
EP3823617A1 (en) 2021-05-26
IL280283B2 (en) 2024-10-01
EP3823617A4 (en) 2022-04-20

Similar Documents

Publication Publication Date Title
JP5417453B2 (ja) タンパク質キナーゼ阻害剤
CN103298460B (zh) 酪蛋白激酶1δ(CK1δ)抑制剂
US20250171421A1 (en) Enantiomerically purified gper agonist for use in treating disease states and conditions
KR101559963B1 (ko) Ａｔｐ-결합 카세트 수송자의 조절자
JP2016147893A (ja) プロテアソーム活性を向上させるための組成物および方法
JP2015532287A (ja) Ｉｒｅ１の調節
CN101827593A (zh) 用于治疗(特别是)囊性纤维化的异噻唑并吡啶酮
EP3596084A1 (en) 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
WO2023131677A1 (en) Compounds containing a hydroxyphenyl moiety and their use
US20240190904A1 (en) Heteroaryl compounds as inhibitors of RIP2 kinase, composition and application thereof
TW202016091A (zh) 一種ｏｔｒ抑制劑的可藥用鹽、晶型及製備方法
KR20190131017A (ko) 선택적 오로라 a 키나아제 억제제
WO2025008526A1 (en) Compounds containing a dialkylaryl moiety and their use
HK1139666A1 (en) Modulators of cystic fibrosis transmembrane conductance regulator
HK1139666B (en) Modulators of cystic fibrosis transmembrane conductance regulator

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000